<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007011</article-id><article-id pub-id-type="pmc">PMC11861731</article-id><article-id pub-id-type="doi">10.3390/v17020254</article-id><article-id pub-id-type="publisher-id">viruses-17-00254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Navigating Epstein&#x02013;Barr Virus (EBV) and Post-Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Liver Transplantation: Current Knowledge and Strategies for Treatment and Surveillance</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6426-1758</contrib-id><name><surname>Chen</surname><given-names>Erin Y.</given-names></name><xref rid="af1-viruses-17-00254" ref-type="aff">1</xref><xref rid="fn1-viruses-17-00254" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5557-3744</contrib-id><name><surname>Dilwali</surname><given-names>Natasha</given-names></name><xref rid="af2-viruses-17-00254" ref-type="aff">2</xref><xref rid="c1-viruses-17-00254" ref-type="corresp">*</xref><xref rid="fn1-viruses-17-00254" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9890-5518</contrib-id><name><surname>Mysore</surname><given-names>Krupa R.</given-names></name><xref rid="af3-viruses-17-00254" ref-type="aff">3</xref><xref rid="fn2-viruses-17-00254" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7579-9425</contrib-id><name><surname>Hassan</surname><given-names>Sara</given-names></name><xref rid="af4-viruses-17-00254" ref-type="aff">4</xref><xref rid="fn2-viruses-17-00254" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Sara Kathryn</given-names></name><xref rid="af2-viruses-17-00254" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7288-5459</contrib-id><name><surname>Karnsakul</surname><given-names>Wikrom</given-names></name><xref rid="af2-viruses-17-00254" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Contini</surname><given-names>Carlo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00254"><label>1</label>School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA; <email>echen41@jh.edu</email></aff><aff id="af2-viruses-17-00254"><label>2</label>Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Johns Hopkins Children&#x02019;s Center, Baltimore, MD 21287, USA; <email>ssmit403@jhmi.edu</email> (S.K.S.); <email>wkarnsa1@jhmi.edu</email> (W.K.)</aff><aff id="af3-viruses-17-00254"><label>3</label>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children&#x02019;s Hospital, Houston, TX 77030, USA; <email>mysore@bcm.edu</email></aff><aff id="af4-viruses-17-00254"><label>4</label>Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, UT Southwestern, Children&#x02019;s Medical Center of Dallas, Dallas, TX 75235, USA; <email>sara.hassan@utsouthwestern.edu</email></aff><author-notes><corresp id="c1-viruses-17-00254"><label>*</label>Correspondence: <email>ndilwal1@jhmi.edu</email>; +1-(908)-447-3426</corresp><fn id="fn1-viruses-17-00254"><label>&#x02020;</label><p>Co-first authors listed alphabetically.</p></fn><fn id="fn2-viruses-17-00254"><label>&#x02021;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>254</elocation-id><history><date date-type="received"><day>16</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Epstein&#x02013;Barr virus (EBV) is strongly associated with the development of post-transplant lymphoproliferative disorder (PTLD) in pediatric liver transplant recipients. PTLD is one of the most common malignancies following liver transplantation and is associated with significant morbidity and mortality. Factors such as EBV&#x02013;serostatus mismatch and prolonged or high levels of immunosuppression impact a patient&#x02019;s risk of developing PTLD. While pre-transplant EBV serological screening and post-transplant monitoring of EBV-DNA levels are strongly recommended, universal guidelines for its prevention and management are lacking. Due to a lack of robust prospective studies, current clinical practices vary widely. The treatment of PTLD typically involves reducing immunosuppression and using targeted therapies such as rituximab, or chemotherapy for refractory cases. This review aims to address our current understanding of EBV&#x02019;s relationship with PTLD, evaluate the available treatment modalities, and highlight evolving strategies for using EBV as a biomarker for PTLD screening and prevention.</p></abstract><kwd-group><kwd>EBV</kwd><kwd>PTLD</kwd><kwd>post-transplant lymphoproliferative disorder</kwd><kwd>pediatric liver transplant</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00254"><title>1. Introduction</title><sec id="sec1dot1-viruses-17-00254"><title>1.1. What Is EBV</title><p>Epstein&#x02013;Barr virus (EBV) is a double-stranded linear DNA virus in the Herpesviridae family that infects over 90% of adults worldwide [<xref rid="B1-viruses-17-00254" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00254" ref-type="bibr">3</xref>]. EBV infection often occurs in childhood and is usually asymptomatic or may present as infectious mononucleosis [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00254" ref-type="bibr">3</xref>]. Beyond acute infection, EBV is implicated in a range of diseases, including multiple sclerosis, Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder (PTLD) [<xref rid="B3-viruses-17-00254" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00254" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00254" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00254" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00254" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00254" ref-type="bibr">8</xref>].</p><p>In transplant recipients, EBV plays a critical role in the pathogenesis of PTLD by driving uncontrolled B-cell proliferation, often due to inadequate T-cell-mediated immune surveillance [<xref rid="B9-viruses-17-00254" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00254" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00254" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>]. The risk of PTLD secondary to EBV is higher in pediatric patients. One study showed that 98% of pediatric PTLD cases were EBV-positive compared to 68% of adult PTLD cases [<xref rid="B14-viruses-17-00254" ref-type="bibr">14</xref>]. In another study, pediatric patients with a post-liver-transplant primary EBV infection were found to be 17 times more likely to develop PTLD than those who had pre-transplant serologies positive for EBV [<xref rid="B15-viruses-17-00254" ref-type="bibr">15</xref>].</p><p>The life cycle of EBV involves three phases: primary infection, latency, and reactivation. Primary infection occurs via the oropharyngeal epithelium, spreading to naive B-cells [<xref rid="B16-viruses-17-00254" ref-type="bibr">16</xref>]. After the initial infection, EBV persists within memory B-cells, which can harbor the virus throughout a person&#x02019;s life [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>,<xref rid="B16-viruses-17-00254" ref-type="bibr">16</xref>]. During latency, EBV expresses latency-associated proteins (e.g., LMP1, LMP2) and EBV nuclear antigens (EBNAs) which facilitate immune evasion, viral replication, and host&#x02013;cell survival [<xref rid="B17-viruses-17-00254" ref-type="bibr">17</xref>,<xref rid="B18-viruses-17-00254" ref-type="bibr">18</xref>]. Latency-associated non-coding RNAs, including Epstein&#x02013;Barr virus-encoded small RNAs (EBERs) and BAMIII fragment A rightward transcripts (BARTs), further contribute to immune modulation and cell survival [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B17-viruses-17-00254" ref-type="bibr">17</xref>]. The reactivation of EBV, typically under immunosuppressive conditions, allows the virus to re-enter its lytic phase, producing new virions and potentially driving PTLD [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>,<xref rid="B16-viruses-17-00254" ref-type="bibr">16</xref>].</p></sec><sec id="sec1dot2-viruses-17-00254"><title>1.2. How EBV Is Detected Currently?</title><p>EBV is detected through antibody serology, nucleic acid amplification testing (NAAT), and EBER flow fluorescence in situ hybridization (EBER flow FISH). During infection, the immune system produces antibodies to its viral components. These antibodies can be detected on serologic assays in immunocompetent hosts and can indicate the temporality of the EBV infection. However, serologic assays are unreliable in immunosuppressed patients due to their altered antibody responses. Studies have shown that immunosuppressed children who had negative EBV serologies often had low-to-undetectable EBV antibody titers after infection. Meanwhile, children who had positive EBV serologies who were then immunosuppressed after transplantation tended to have high EBV antibody titers [<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B18-viruses-17-00254" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00254" ref-type="bibr">19</xref>].</p><p>EBV DNAemia can be measured through NAAT. In immunocompetent hosts, EBV DNAemia is often low or undetectable. During times of immune disruption or immunosuppression, these levels can transiently rise and become detectable with NAAT, making surveillance crucial. However, the quantification of the EBV viral load can vary greatly, depending on what is being measured (whole blood vs. plasma) and the quality of the NAAT assay [<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B20-viruses-17-00254" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00254" ref-type="bibr">21</xref>]. Per the International Pediatric Transplant Association (IPTA) guidelines, either whole blood or plasma can be used, each with its own potential benefits, as whole blood is more sensitive, while plasma is more specific [<xref rid="B20-viruses-17-00254" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00254" ref-type="bibr">21</xref>]. EBER flow FISH, using EBV-encoded small RNAs (EBERs), is an emerging tool that identifies infected cells in both their lytic and latent stages. Unlike PCR, it can differentiate EBV infections across various cell types, offering insights into the pathogenesis and disease mechanisms of EBV (<xref rid="viruses-17-00254-t001" ref-type="table">Table 1</xref>) [<xref rid="B20-viruses-17-00254" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00254" ref-type="bibr">21</xref>,<xref rid="B22-viruses-17-00254" ref-type="bibr">22</xref>,<xref rid="B23-viruses-17-00254" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00254" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-00254" ref-type="bibr">25</xref>].</p></sec></sec><sec id="sec2-viruses-17-00254"><title>2. Post-Transplant Lymphoproliferative Disorder (PTLD)</title><sec id="sec2dot1-viruses-17-00254"><title>2.1. Why Does It Matter in Pediatric Solid Organ Transplants?</title><p>PTLD accounts for approximately 70% of all malignancies diagnosed following SOT in pediatric patients and occurs in up to 20% of cases, with mortality rates reaching 50% depending on the transplanted organ [<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>,<xref rid="B26-viruses-17-00254" ref-type="bibr">26</xref>,<xref rid="B27-viruses-17-00254" ref-type="bibr">27</xref>]. In pediatric liver transplantation, its prevalence is approximately 2&#x02013;8%, with a mortality of 44% [<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B28-viruses-17-00254" ref-type="bibr">28</xref>]. The outcomes in SOT recipients are less favorable due to the limited effectiveness of preemptive EBV therapies compared to hematopoietic stem cell transplant (HSCT) settings [<xref rid="B26-viruses-17-00254" ref-type="bibr">26</xref>,<xref rid="B29-viruses-17-00254" ref-type="bibr">29</xref>]. Beyond mortality, PTLD impacts long-term SOT outcomes, serving as a risk factor for chronic allograft rejection and graft loss, often necessitating re-transplantation [<xref rid="B30-viruses-17-00254" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot2-viruses-17-00254"><title>2.2. Clinical Presentation</title><p>The clinical presentation and symptoms of PTLD are highly variable and non-specific (<xref rid="viruses-17-00254-f001" ref-type="fig">Figure 1</xref>). Patients may be asymptomatic or present with fever, malaise, weight loss, anorexia, diarrhea, and night sweats. Some children present with classic infectious mononucleosis symptoms and lymphadenopathy. PTLD can present with focal symptoms related to the affected organ or, rarely, with disseminated multiorgan disease that resembles sepsis. Patients may experience a sore throat, voice changes, snoring, cough, or trouble breathing if tonsillar lymph nodes are affected [<xref rid="B31-viruses-17-00254" ref-type="bibr">31</xref>,<xref rid="B32-viruses-17-00254" ref-type="bibr">32</xref>,<xref rid="B33-viruses-17-00254" ref-type="bibr">33</xref>]. Gastrointestinal involvement is common, presenting with hepatosplenomegaly, gastrointestinal bleeding, and abdominal pain [<xref rid="B34-viruses-17-00254" ref-type="bibr">34</xref>,<xref rid="B35-viruses-17-00254" ref-type="bibr">35</xref>]. While rare, PTLD can sometimes involve the central nervous system and cause focal neurologic deficits [<xref rid="B35-viruses-17-00254" ref-type="bibr">35</xref>,<xref rid="B36-viruses-17-00254" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00254" ref-type="bibr">37</xref>]. PTLD of the allograft organ can also occur, and acute organ rejection is often mistaken for PTLD. About 33% of pediatric liver transplant PTLD manifestations involve the liver allograft [<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B38-viruses-17-00254" ref-type="bibr">38</xref>]. Overall, children more commonly present with isolated cervical lymphadenopathy, intussusception, mesenteric adenopathy, and bowel wall thickening compared to adults, who are more likely to have extra-nodal involvement of the gastrointestinal tract, allograft, and central nervous system [<xref rid="B39-viruses-17-00254" ref-type="bibr">39</xref>]. PTLD presents with a bimodal distribution, with most cases occurring within one year of transplantation, and the rest presenting five to ten years after transplantation [<xref rid="B40-viruses-17-00254" ref-type="bibr">40</xref>]. Progression can vary widely, from a rapidly advancing disease to prolonged, fluctuating courses.</p></sec><sec id="sec2dot3-viruses-17-00254"><title>2.3. Diagnosis</title><p>The definitive diagnosis of PTLD relies on a tissue biopsy, which allows for its histological evaluation and classification. Under the 2017 WHO guidelines, PTLD was categorized into four types: non-destructive, polymorphic, monomorphic, and classic Hodgkin lymphoma [<xref rid="B41-viruses-17-00254" ref-type="bibr">41</xref>,<xref rid="B42-viruses-17-00254" ref-type="bibr">42</xref>]. In 2022, the WHO updated this classification to emphasize different forms of immune dysfunction, aligning more closely with clinical scenarios and patient management (<xref rid="viruses-17-00254-t002" ref-type="table">Table 2</xref>) [<xref rid="B10-viruses-17-00254" ref-type="bibr">10</xref>,<xref rid="B43-viruses-17-00254" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00254" ref-type="bibr">44</xref>]. Comprehensive laboratory and imaging studies are crucial in supporting its diagnosis and staging. The initial workup often includes a complete blood count, complete metabolic panel, lactate dehydrogenase, uric acid, EBV PCR in previously EBV-negative patients, and EBV serologies. If the concern about PTLD is high, computed tomography (CT) or magnetic resonance imaging (MRI) with contrast is obtained to localize the areas of involvement and stage the disease. PET-CT is particularly valuable for detecting metabolically active lesions and staging [<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>,<xref rid="B43-viruses-17-00254" ref-type="bibr">43</xref>,<xref rid="B45-viruses-17-00254" ref-type="bibr">45</xref>]. Staging is based on current defined guidelines for staging lymphoma [<xref rid="B46-viruses-17-00254" ref-type="bibr">46</xref>]. If gastrointestinal symptoms are present, a gastrointestinal endoscopy is often performed to localize and biopsy the potential lesion [<xref rid="B13-viruses-17-00254" ref-type="bibr">13</xref>,<xref rid="B34-viruses-17-00254" ref-type="bibr">34</xref>,<xref rid="B35-viruses-17-00254" ref-type="bibr">35</xref>]. The prompt identification and classification of PTLD are critical for guiding timely, targeted treatment to improve outcomes (<xref rid="viruses-17-00254-f001" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec id="sec3-viruses-17-00254"><title>3. The Connection Between EBV and PTLD</title><sec><title>Epidemiology</title><p>The rising incidence of PTLD can be attributed to multiple factors. One of the primary reasons is the increasing number of SOTs performed, particularly liver transplants (LTs), which inherently increases the pool of individuals at risk for PTLD. Additionally, there has been a growing awareness about PTLD, leading to more vigilant monitoring and recognition of the condition. Furthermore, advancements in diagnostic techniques, including more sensitive imaging modalities and molecular testing, have improved our ability to detect PTLD at earlier stages or in less obvious clinical presentations, contributing to the observed increase in reported cases [<xref rid="B47-viruses-17-00254" ref-type="bibr">47</xref>].</p><p>The prevalence of PTLD in LT recipients is impacted by several factors, resulting in a 2&#x02013;12% incidence rate. One of the most significant factors is the immunosuppressive regimen used to prevent organ rejection, as more intense or prolonged immunosuppression can increase the risk of a patient developing PTLD. Additionally, the recipient&#x02019;s EBV serostatus plays a critical role, as those who are EBV-negative at the time of transplant are at a higher risk when exposed to the virus post-transplant. Furthermore, EBV donor&#x02013;recipient mismatch significantly elevates risk, particularly when an EBV-positive donor transmits the virus to an EBV-negative recipient [<xref rid="B15-viruses-17-00254" ref-type="bibr">15</xref>,<xref rid="B47-viruses-17-00254" ref-type="bibr">47</xref>,<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>,<xref rid="B49-viruses-17-00254" ref-type="bibr">49</xref>].</p></sec></sec><sec id="sec4-viruses-17-00254"><title>4. Pathophysiology</title><p>Approximately 55&#x02013;75% of PTLDs are associated with an EBV infection linked to a primary infection, reactivation, or donor transmission [<xref rid="B10-viruses-17-00254" ref-type="bibr">10</xref>]. EBV reactivation can occur due to a variety of factors. The use of immunosuppressant mycophenolate mofetil (MMF) post-transplant has been shown to reduce V&#x003b3;2+ T cell proliferation, a T-cell critical for both innate and adaptive immunity against EBV-infected cells [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B50-viruses-17-00254" ref-type="bibr">50</xref>,<xref rid="B51-viruses-17-00254" ref-type="bibr">51</xref>]. EBV reactivation is also frequently observed in co-infections such as cytomegalovirus, syphilis, human papillomavirus, Kaposi sarcoma-associated herpesvirus, and COVID-19 [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>,<xref rid="B52-viruses-17-00254" ref-type="bibr">52</xref>]. Additionally, non-infectious factors such as radiation, oxidative and cellular stress, B-cell maturation, and psychological stress have been linked to increased EBV viral load and reactivation [<xref rid="B2-viruses-17-00254" ref-type="bibr">2</xref>].</p><p>While the precise mechanisms at play remain unclear, the EBV genome is found in &#x0003e;90% of B-cell PTLD cases occurring within the first year after a SOT [<xref rid="B11-viruses-17-00254" ref-type="bibr">11</xref>,<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>]. The host immune system typically regulates EBV-infected latent cell proliferation and viral reactivation through mechanisms such as cytotoxic T lymphocytes (CTLs), which target EBV antigens like LMP1 and EBNA2 [<xref rid="B9-viruses-17-00254" ref-type="bibr">9</xref>,<xref rid="B12-viruses-17-00254" ref-type="bibr">12</xref>,<xref rid="B16-viruses-17-00254" ref-type="bibr">16</xref>,<xref rid="B53-viruses-17-00254" ref-type="bibr">53</xref>]. EBV latent membrane proteins 1 and 2a (LMP-1 and LMP-2a) mimic CD40 and B-cell receptor growth signals, respectively, providing survival signals to B-cells. CD40 activation inhibits viral lytic infection, while interleukin-10 secretion by EBV stimulates B-cell proliferation [<xref rid="B10-viruses-17-00254" ref-type="bibr">10</xref>]. These processes, combined with EBV oncogene expression, immunosuppression, chronic antigen exposure, and impaired T-cell surveillance, contribute to B-cell transformation, proliferation, and apoptosis inhibition, driving PTLD development [<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>,<xref rid="B54-viruses-17-00254" ref-type="bibr">54</xref>].</p></sec><sec id="sec5-viruses-17-00254"><title>5. Donor/Recipient Status</title><p>Donor-transmitted EBV infections are particularly common in EBV-mismatched patients (donor seropositive/recipient seronegative), especially in children who are often EBV-na&#x000ef;ve [<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>]. Monitoring recipients&#x02019; EBV serological status and EBV DNAemia post-transplant has proven effective in stratifying EBV risk. For instance, Bernabeu et al. found that approximately 20% of asymptomatic post-transplant children carried high EBV loads for months to years following a primary infection [<xref rid="B15-viruses-17-00254" ref-type="bibr">15</xref>,<xref rid="B55-viruses-17-00254" ref-type="bibr">55</xref>].</p></sec><sec id="sec6-viruses-17-00254"><title>6. EBV-Positive vs. EBV-Negative PTLD</title><p>In a large analysis of over 160,000 pediatric and adult liver transplant recipients, Dharnidharka et al. highlighted an elevated PTLD risk in EBV-seronegative individuals [<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>,<xref rid="B56-viruses-17-00254" ref-type="bibr">56</xref>]. Early-onset PTLDs are predominantly EBV-positive and present within the first-year post-transplant, while EBV-negative PTLDs typically manifest 5&#x02013;10 years later. EBV-positive PTLD also tends to present with a polymorphic histology, while EBV-negative PTLD is frequently monomorphic and resembles the lymphomas found in immunocompetent hosts [<xref rid="B57-viruses-17-00254" ref-type="bibr">57</xref>].</p><p>Although EBV plays a significant role, the pathogenesis of PTLD also involves genetic alterations, such as chromosomal translocations, gene mutations, and epigenetic changes. Further, other viral infections (e.g., human herpes virus 5, 6, and 8), hit-and-run EBV infections, and chronic antigenic stimulation by the allograft, including antibody-mediated rejection, may contribute to EBV-negative PTLD, although this remains unconfirmed [<xref rid="B57-viruses-17-00254" ref-type="bibr">57</xref>,<xref rid="B58-viruses-17-00254" ref-type="bibr">58</xref>].</p></sec><sec id="sec7-viruses-17-00254"><title>7. Treatment of PTLD</title><p>The goal of PTLD treatment is to achieve remission while preserving the allograft. Due to the rarity of PTLD, most evidence is derived from retrospective studies [<xref rid="B59-viruses-17-00254" ref-type="bibr">59</xref>]. First-line management includes reducing immunosuppression (RIS), followed by rituximab (anti-CD20 monoclonal antibody) and, in some cases, chemotherapy (<xref rid="viruses-17-00254-f002" ref-type="fig">Figure 2</xref>; <xref rid="viruses-17-00254-t003" ref-type="table">Table 3</xref>). Surgery and radiation are limited to isolated or palliative cases [<xref rid="B39-viruses-17-00254" ref-type="bibr">39</xref>]. Novel therapies including immunotherapy, cytokine treatment, and anti-EBV-based therapy continue to be explored (<xref rid="viruses-17-00254-f002" ref-type="fig">Figure 2</xref>; <xref rid="viruses-17-00254-t003" ref-type="table">Table 3</xref>). Currently, there are no standardized treatment regimens for PTLD. Therapy should be individualized based on the stage and type of PTLD. Multidisciplinary approaches with the early involvement of oncology are essential for the management of PTLD.</p><list list-type="order"><list-item><p>Reducing Immunosuppression (RIS):</p></list-item></list><p>RIS aims to restore recipient immunity by enabling EBV-specific T-lymphocyte proliferation [<xref rid="B60-viruses-17-00254" ref-type="bibr">60</xref>]. Early, low-burden, EBV-driven cases respond best to RIS, but outcomes are less favorable in aggressive disease or late-onset PTLD [<xref rid="B56-viruses-17-00254" ref-type="bibr">56</xref>]. The risks include a delayed response (3&#x02013;5 weeks), graft rejection, and organ failure [<xref rid="B59-viruses-17-00254" ref-type="bibr">59</xref>]. Protocols vary by disease severity and transplant center, often involving calcineurin inhibitor reduction and antimetabolite discontinuation [<xref rid="B54-viruses-17-00254" ref-type="bibr">54</xref>]. In pediatric solid organ transplant patients, predictors for a poor response to RIS alone include CD20 or EBV negativity, late-onset PTLD, or neural involvement [<xref rid="B39-viruses-17-00254" ref-type="bibr">39</xref>,<xref rid="B61-viruses-17-00254" ref-type="bibr">61</xref>,<xref rid="B62-viruses-17-00254" ref-type="bibr">62</xref>].</p><list list-type="simple"><list-item><label>2.</label><p>Rituximab:</p></list-item></list><p>Rituximab is a chimeric murine and human monoclonal anti-CD20 antibody. The CD20 antigen is found on B-cell lymphocytes, where rituximab can bind and mediate B-cell lysis and CD20+ tumors. It is typically used after RIS failure or as part of sequential therapy with chemotherapy [<xref rid="B61-viruses-17-00254" ref-type="bibr">61</xref>,<xref rid="B63-viruses-17-00254" ref-type="bibr">63</xref>]. As with RIS, monotherapy with rituximab has not shown a long-term event-free survival&#x02014;in a combined analysis of two prospective trials of rituximab monotherapy in PTLD, 26% of complete and partial responders required further therapy within 1 year [<xref rid="B63-viruses-17-00254" ref-type="bibr">63</xref>,<xref rid="B64-viruses-17-00254" ref-type="bibr">64</xref>,<xref rid="B65-viruses-17-00254" ref-type="bibr">65</xref>]. Recent data have shown that the early introduction of rituximab in PTLD improves outcomes, with a reported overall survival of 73% compared to 33% in those who received frontline rituximab treatment [<xref rid="B65-viruses-17-00254" ref-type="bibr">65</xref>].</p><list list-type="simple"><list-item><label>3.</label><p>Chemotherapy:</p></list-item></list><p>Historically, chemotherapy used for lymphoproliferative disorders has not been used in SOT recipients due to its high treatment-related mortality (TRM) and the risk of graft rejection [<xref rid="B62-viruses-17-00254" ref-type="bibr">62</xref>]. However, those who can tolerate it can achieve lasting remission from PTLD [<xref rid="B39-viruses-17-00254" ref-type="bibr">39</xref>,<xref rid="B61-viruses-17-00254" ref-type="bibr">61</xref>]. The PTLD-1 trial established that 20% of patients achieved complete remission with monotherapy and 57% achieved complete remission with sequential rituximab and CHOP chemotherapy for aggressive cases [<xref rid="B66-viruses-17-00254" ref-type="bibr">66</xref>,<xref rid="B67-viruses-17-00254" ref-type="bibr">67</xref>]. In terms of pediatric PTLD, a pilot phase 2 trial was carried out with the Children&#x02019;s Oncology Group, with a two-year event-free survival rate of 77% and an overall survival rate of 80% found [<xref rid="B68-viruses-17-00254" ref-type="bibr">68</xref>]. If chemotherapy is utilized, supportive measures such as prophylactic antibodies, continued RIS, and the use of growth factors should be considered [<xref rid="B62-viruses-17-00254" ref-type="bibr">62</xref>].</p><list list-type="simple"><list-item><label>4.</label><p>Novel Therapies:</p></list-item></list><p>The treatment of PTLD in transplant recipients generates special challenges due to organ dysfunction with the long-term use of calcineurin inhibitors, concerns about graft function, and the potential for toxicity and higher infection risk. These issues have led to the consideration of novel treatment options [<xref rid="B61-viruses-17-00254" ref-type="bibr">61</xref>]:<list list-type="simple"><list-item><label>A.</label><p>CD30 Targeting: The CD30 antigen is an activation marker expressed by activated B and T lymphocytes, recently found to be commonly expressed in all types of PTLD. Brentuximab vedotin, an anti-CD30 antibody&#x02013;drug conjugate, shows promise in CD30-positive PTLD when administered concurrently with rituximab [<xref rid="B69-viruses-17-00254" ref-type="bibr">69</xref>,<xref rid="B70-viruses-17-00254" ref-type="bibr">70</xref>,<xref rid="B71-viruses-17-00254" ref-type="bibr">71</xref>].</p></list-item><list-item><label>B.</label><p>T Cell Therapy: Donor-derived EBV-specific cytotoxic T-lymphocyte (CTL) infusions have shown efficacy in solid organ transplant recipients, with response rates exceeding 50%. Due to immune suppression in transplant recipients, the cytotoxic T-cell response is poor in PTLD. Donor-derived anti-EBV cytotoxic T lymphocytes (CTL) can be infused into a patient, altering their EBV-specific cellular immune response and leading to PTLD regression [<xref rid="B72-viruses-17-00254" ref-type="bibr">72</xref>]. In SOT, CTL infusions have achieved overall response rates of 64% at five weeks and 52% at six months [<xref rid="B72-viruses-17-00254" ref-type="bibr">72</xref>]. In an ongoing phase 3 trial (ALLELE), the allogenic EBV-CTL treatment tabelecleucel showed an objective response in 52% of SOT patients with relapsed or refractory PTLD without significant treatment-related adverse events [<xref rid="B73-viruses-17-00254" ref-type="bibr">73</xref>].</p></list-item><list-item><label>C.</label><p>Interleukin-6: Anti-IL-6 monoclonal antibodies have led to partial or complete remission in small cohorts. IL-6 promotes the growth of EBV-infected B-cells and patients with PTLD have high levels of IL-6. Based on this, anti-IL6 monoclonal antibodies have been trialed, which led to complete remission in 45% and partial remission in 25% of the 12 patients [<xref rid="B74-viruses-17-00254" ref-type="bibr">74</xref>]. However, the data are limited, and further study is needed.</p></list-item></list></p><table-wrap position="anchor" id="viruses-17-00254-t003"><object-id pub-id-type="pii">viruses-17-00254-t003_Table 3</object-id><label>Table 3</label><caption><p>Treatment regimens of PTLD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosing</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risks</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Reduction in Immunosuppression</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>N/A</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delayed response (3&#x02013;5 wks), graft rejection, organ failure [<xref rid="B62-viruses-17-00254" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rituximab (monotherapy)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Four intravenous (IV) infusions, each of 375 mg/m<sup>2</sup>, on days 1, 8, 15, and 22 of treatment [<xref rid="B63-viruses-17-00254" ref-type="bibr">63</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe infection, neutropenia, hypogammaglobulinemia </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Chemotherapy (CHOP) w/Rituximab</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Six cycles, 3 weeks apart<break/>Cycles 1 and 2: <italic toggle="yes">Cyclophosphamide</italic> (600 mg/m<sup>2</sup> intravenous) day 1 <italic toggle="yes">prednisone</italic> (1 mg/kg orally twice a day) or <italic toggle="yes">methylprednisolone</italic> (0.8 mg/kg intravenous every 12 h) on days 1&#x02013;5, and <italic toggle="yes">rituximab</italic> (375 mg/m<sup>2</sup> intravenous) on days 1, 8 and 15<break/>Cycles 3&#x02013;6: same as above, without rituximab [<xref rid="B68-viruses-17-00254" ref-type="bibr">68</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment-related mortality, graft rejection [<xref rid="B68-viruses-17-00254" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Targeting CD30 (Brentuximab vedotin) w/Rituximab</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction:<break/><italic toggle="yes">Rituximab</italic> 375 mg/m<sup>2</sup> given on days 1, 8, 15, and 22 of treatment<break/><italic toggle="yes">Brentuximab vedotin</italic> 1.2&#x02009;mg/kg given on days 1, 8, and 15<break/><underline>Maintenance:</underline><break/><italic toggle="yes">Rituximab</italic> 375 mg/m<sup>2</sup> every 6 wks<break/><italic toggle="yes">Brentuximab vedotin</italic> 1.8&#x02009;mg/kg every 3&#x02009;weeks [<xref rid="B71-viruses-17-00254" ref-type="bibr">71</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment-related toxicity&#x02014;infection, febrile neutropenia, peripheral neuropathy, pancreatitis [<xref rid="B71-viruses-17-00254" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>T-Cell Therapy (e.g., tabelecleucel)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly intravenous infusions of CTLs (2 &#x000d7; 10<sup>6</sup> CTLs/kg) for total of 4 weeks [<xref rid="B72-viruses-17-00254" ref-type="bibr">72</xref>,<xref rid="B73-viruses-17-00254" ref-type="bibr">73</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine release syndrome, infusion toxicity [<xref rid="B73-viruses-17-00254" ref-type="bibr">73</xref>,<xref rid="B75-viruses-17-00254" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Anti-Interleukin-6 (IL-6) Antibodies</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 0.8 mg/kg per day for 15 days [<xref rid="B74-viruses-17-00254" ref-type="bibr">74</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection, thrombocytopenia, neutropenia, dyslipidemia, elevated liver enzymes [<xref rid="B76-viruses-17-00254" ref-type="bibr">76</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>CHOP = cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone; CTL = Cytotoxic T-Lymphocytes.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec8-viruses-17-00254"><title>8. Screening and Surveillance</title><p>Pre-transplant EBV serological screening of both the donor and recipient is critical for risk stratification. Most commonly seen post-transplant, EBV DNAemia is monitored using PCR assays of whole blood or plasma, though practices vary globally. Unfortunately, there are no specific criteria used to define EBV DNAemia cut off values to start preemptive management, as EBV levels at PTLD diagnosis are quite variable. Sustained high viral loads are associated with increased PTLD risk and hence serial monitoring is advocated for [<xref rid="B15-viruses-17-00254" ref-type="bibr">15</xref>,<xref rid="B77-viruses-17-00254" ref-type="bibr">77</xref>,<xref rid="B78-viruses-17-00254" ref-type="bibr">78</xref>,<xref rid="B79-viruses-17-00254" ref-type="bibr">79</xref>]. Since the risk of PTLD has been linked to immunosuppression use, and its incidence is highest in the first year post-transplantation, transplant centers generally screen for EBV titers in the blood or plasma more frequently during this period [<xref rid="B80-viruses-17-00254" ref-type="bibr">80</xref>]. The International Pediatric Transplant Association (IPTA) recently proposed surveillance guidelines in 2023. For EBV-negative patients who receive an organ from EBV-positive donors, they propose weekly EBV PCR surveillance for three months post-transplant, followed by biweekly surveillance until six months, and then monthly until one year. If their EBV PCR becomes positive, then weekly EBV viral load monitoring should be performed until the viral load peaks and begins down-trending after two&#x02013;four weeks. EBV viral load monitoring is then adjusted to biweekly, monthly, and then every three months until the viral load is undetectable [<xref rid="B21-viruses-17-00254" ref-type="bibr">21</xref>]. A younger age at transplant and seronegativity pre-transplant are risk factors for the development of early PTLD [<xref rid="B15-viruses-17-00254" ref-type="bibr">15</xref>]. Though universal cutoff values remain undefined, centers commonly preemptively adjust immunosuppression and use rituximab for high EBV loads [<xref rid="B48-viruses-17-00254" ref-type="bibr">48</xref>,<xref rid="B80-viruses-17-00254" ref-type="bibr">80</xref>,<xref rid="B81-viruses-17-00254" ref-type="bibr">81</xref>]. Standardized algorithms for EBV monitoring, risk-based immunosuppression reduction, and preemptive rituximab use are needed in pediatric liver transplantation.</p></sec><sec sec-type="conclusions" id="sec9-viruses-17-00254"><title>9. Conclusions</title><p>PTLD is a rising concern in pediatric liver transplantation and is strongly associated with EBV infection. Effective prevention and treatment strategies, including immunosuppression management, rituximab, and novel therapies, continue to evolve. However, systematic EBV monitoring and risk-based interventions remain critical in mitigating the incidence of PTLD and improving outcomes. Further research is mandatory to determine the best management strategies for children found to be at higher risk for PTLD, how to approach post-transplant patients with EBV-DNAemia, and whether other potential biomarkers can be used to assess the risk of PTLD developing in pediatric liver transplant patients [<xref rid="B77-viruses-17-00254" ref-type="bibr">77</xref>,<xref rid="B81-viruses-17-00254" ref-type="bibr">81</xref>].</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>All authors contributed to the work presented in this paper. E.Y.C. and N.D.: literature review, manuscript writing, editing, and preparation. K.R.M. and S.H.: manuscript writing and editing; W.K. and S.K.S.: manuscript writing, editing, and supervision of the project. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00254"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de-Th&#x000e9;</surname><given-names>G.</given-names></name>
<name><surname>Day</surname><given-names>N.E.</given-names></name>
<name><surname>Geser</surname><given-names>A.</given-names></name>
<name><surname>Lavou&#x000e9;</surname><given-names>M.F.</given-names></name>
<name><surname>Ho</surname><given-names>J.H.</given-names></name>
<name><surname>Simons</surname><given-names>M.J.</given-names></name>
<name><surname>Sohier</surname><given-names>R.</given-names></name>
<name><surname>Tukei</surname><given-names>P.</given-names></name>
<name><surname>Vonka</surname><given-names>V.</given-names></name>
<name><surname>Zavadova</surname><given-names>H.</given-names></name>
</person-group><article-title>Sero-epidemiology of the Epstein-Barr virus: Preliminary analysis of an international study&#x02014;A review</article-title><source>IARC Sci. Publ.</source><year>1975</year><volume>11</volume><fpage>3</fpage><lpage>16</lpage></element-citation></ref><ref id="B2-viruses-17-00254"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sausen</surname><given-names>D.G.</given-names></name>
<name><surname>Bhutta</surname><given-names>M.S.</given-names></name>
<name><surname>Gallo</surname><given-names>E.S.</given-names></name>
<name><surname>Dahari</surname><given-names>H.</given-names></name>
<name><surname>Borenstein</surname><given-names>R.</given-names></name>
</person-group><article-title>Stress-Induced Epstein-Barr Virus Reactivation</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1380</elocation-id><pub-id pub-id-type="doi">10.3390/biom11091380</pub-id><pub-id pub-id-type="pmid">34572593</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00254"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunmire</surname><given-names>S.K.</given-names></name>
<name><surname>Verghese</surname><given-names>P.S.</given-names></name>
<name><surname>Balfour</surname><given-names>H.H.</given-names></name>
</person-group><article-title>Primary Epstein-Barr virus infection</article-title><source>J. Clin. Virol.</source><year>2018</year><volume>102</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2018.03.001</pub-id><pub-id pub-id-type="pmid">29525635</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00254"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ou</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Hou</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>W.</given-names></name>
<name><surname>Dong</surname><given-names>Q.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
</person-group><article-title>Associations of Infectious Agents with Alzheimer&#x02019;s Disease: A Systematic Review and Meta-Analysis</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2020</year><volume>75</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.3233/JAD-191337</pub-id><pub-id pub-id-type="pmid">32280095</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00254"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Houen</surname><given-names>G.</given-names></name>
<name><surname>Trier</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Epstein-Barr Virus and Systemic Autoimmune Diseases</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><elocation-id>587380</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.587380</pub-id><pub-id pub-id-type="pmid">33488588</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00254"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
<name><surname>Munger</surname><given-names>K.L.</given-names></name>
<name><surname>L&#x000fc;nemann</surname><given-names>J.D.</given-names></name>
</person-group><article-title>The initiation and prevention of multiple sclerosis</article-title><source>Nat. Rev. Neurol.</source><year>2012</year><volume>8</volume><fpage>602</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2012.198</pub-id><pub-id pub-id-type="pmid">23045241</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00254"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosdahl</surname><given-names>N.</given-names></name>
<name><surname>Madsen</surname><given-names>M.</given-names></name>
<name><surname>Storm</surname><given-names>H.H.</given-names></name>
<name><surname>Askling</surname><given-names>J.</given-names></name>
<name><surname>Hamilton-Dutoit</surname><given-names>S.</given-names></name>
<name><surname>Melbye</surname><given-names>M.</given-names></name>
<name><surname>Frisch</surname><given-names>M.</given-names></name>
<name><surname>Helle</surname><given-names>B.K.</given-names></name>
<name><surname>Rostgaard</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Characteristics of Hodgkin&#x02019;s Lymphoma after Infectious Mononucleosis</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>1324</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa023141</pub-id><pub-id pub-id-type="pmid">14523140</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00254"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>A.</given-names></name>
<name><surname>David</surname><given-names>A.</given-names></name>
</person-group><article-title>Thorley-Lawson Persistence of the Epstein&#x02013;Barr Virus and the Origins of Associated Lymphomas</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1328</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1056/NEJMra032015</pub-id><pub-id pub-id-type="pmid">15044644</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00254"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haque</surname><given-names>T.</given-names></name>
<name><surname>Amlot</surname><given-names>P.L.</given-names></name>
<name><surname>Helling</surname><given-names>N.</given-names></name>
<name><surname>Thomas</surname><given-names>J.A.</given-names></name>
<name><surname>Sweny</surname><given-names>P.</given-names></name>
<name><surname>Rolles</surname><given-names>K.</given-names></name>
<name><surname>Burroughs</surname><given-names>A.K.</given-names></name>
<name><surname>Prentice</surname><given-names>H.G.</given-names></name>
<name><surname>Crawford</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients</article-title><source>J. Immunol.</source><year>1998</year><volume>160</volume><fpage>6204</fpage><lpage>6209</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.160.12.6204</pub-id><pub-id pub-id-type="pmid">9637540</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00254"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marques-Piubelli</surname><given-names>M.L.</given-names></name>
<name><surname>Salas</surname><given-names>Y.I.</given-names></name>
<name><surname>Pachas</surname><given-names>C.</given-names></name>
<name><surname>Becker-Hecker</surname><given-names>R.</given-names></name>
<name><surname>Vega</surname><given-names>F.</given-names></name>
<name><surname>Miranda</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review</article-title><source>Pathology</source><year>2020</year><volume>52</volume><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.pathol.2019.09.006</pub-id><pub-id pub-id-type="pmid">31706670</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00254"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dharnidharka</surname><given-names>V.R.</given-names></name>
</person-group><article-title>Comprehensive review of post-organ transplant hematologic cancers</article-title><source>Am. J. Transplant.</source><year>2018</year><volume>18</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1111/ajt.14603</pub-id><pub-id pub-id-type="pmid">29178667</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00254"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>R.D.</given-names></name>
<name><surname>Sokol</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Epstein-Barr virus and post-transplant lymphoproliferative disease</article-title><source>Pediatr. Transplant.</source><year>2002</year><volume>6</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3046.2002.02043.x</pub-id><pub-id pub-id-type="pmid">12453197</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00254"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okamoto</surname><given-names>T.</given-names></name>
<name><surname>Okajima</surname><given-names>H.</given-names></name>
<name><surname>Uebayashi</surname><given-names>E.Y.</given-names></name>
<name><surname>Ogawa</surname><given-names>E.</given-names></name>
<name><surname>Yamada</surname><given-names>Y.</given-names></name>
<name><surname>Umeda</surname><given-names>K.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>H.</given-names></name>
<name><surname>Hatano</surname><given-names>E.</given-names></name>
</person-group><article-title>Management of Epstein&#x02013;Barr Virus Infection and Post-Transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation</article-title><source>JCM</source><year>2022</year><volume>11</volume><elocation-id>2166</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11082166</pub-id><pub-id pub-id-type="pmid">35456259</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00254"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Nalesnik</surname><given-names>M.</given-names></name>
<name><surname>Reyes</surname><given-names>J.</given-names></name>
<name><surname>Pokharna</surname><given-names>R.</given-names></name>
<name><surname>Mazariegos</surname><given-names>G.</given-names></name>
<name><surname>Green</surname><given-names>M.</given-names></name>
<name><surname>Eghtesad</surname><given-names>B.</given-names></name>
<name><surname>Marsh</surname><given-names>W.</given-names></name>
<name><surname>Cacciarelli</surname><given-names>T.</given-names></name>
<name><surname>Fontes</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience</article-title><source>Ann. Surg.</source><year>2002</year><volume>236</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1097/00000658-200210000-00005</pub-id><pub-id pub-id-type="pmid">12368671</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00254"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quintero Bernabeu</surname><given-names>J.</given-names></name>
<name><surname>Juamperez</surname><given-names>J.</given-names></name>
<name><surname>Mercadal-Hally</surname><given-names>M.</given-names></name>
<name><surname>Larrarte King</surname><given-names>M.</given-names></name>
<name><surname>Gallego Melcon</surname><given-names>S.</given-names></name>
<name><surname>Gros Subias</surname><given-names>L.</given-names></name>
<name><surname>S&#x000e1;bado &#x000c1;lvarez</surname><given-names>C.</given-names></name>
<name><surname>Soler-Palacin</surname><given-names>P.</given-names></name>
<name><surname>Melendo P&#x000e9;rez</surname><given-names>S.</given-names></name>
<name><surname>Esperalba</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients</article-title><source>Pediatr. Transplant.</source><year>2022</year><volume>26</volume><fpage>e14292</fpage><pub-id pub-id-type="doi">10.1111/petr.14292</pub-id><pub-id pub-id-type="pmid">35466492</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00254"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Robertson</surname><given-names>E.S.</given-names></name>
</person-group><article-title>Epstein&#x02013;Barr Virus History and Pathogenesis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>714</elocation-id><pub-id pub-id-type="doi">10.3390/v15030714</pub-id><pub-id pub-id-type="pmid">36992423</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00254"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paudel</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>N.</given-names></name>
</person-group><article-title>Epstein-Barr virus noncoding RNA EBER1 promotes the expression of a ribosomal protein paralog to boost oxidative phosphorylation</article-title><source>bioRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1002/jmv.29869</pub-id></element-citation></ref><ref id="B18-viruses-17-00254"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cen</surname><given-names>H.</given-names></name>
<name><surname>Williams</surname><given-names>P.A.</given-names></name>
<name><surname>McWilliams</surname><given-names>H.P.</given-names></name>
<name><surname>Breinig</surname><given-names>M.C.</given-names></name>
<name><surname>Ho</surname><given-names>M.</given-names></name>
<name><surname>McKnight</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders</article-title><source>Blood</source><year>1993</year><volume>81</volume><fpage>1393</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1182/blood.V81.5.1393.1393</pub-id><pub-id pub-id-type="pmid">8382973</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00254"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hopwood</surname><given-names>P.</given-names></name>
<name><surname>Crawford</surname><given-names>D.H.</given-names></name>
</person-group><article-title>The role of EBV in post-transplant malignancies: A review</article-title><source>J. Clin. Pathol.</source><year>2000</year><volume>53</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1136/jcp.53.4.248</pub-id><pub-id pub-id-type="pmid">10823119</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00254"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>M.</given-names></name>
<name><surname>Fukuda</surname><given-names>A.</given-names></name>
<name><surname>Ogura</surname><given-names>M.</given-names></name>
<name><surname>Shimizu</surname><given-names>S.</given-names></name>
<name><surname>Uchida</surname><given-names>H.</given-names></name>
<name><surname>Yanagi</surname><given-names>Y.</given-names></name>
<name><surname>Ishikawa</surname><given-names>Y.</given-names></name>
<name><surname>Sakamoto</surname><given-names>S.</given-names></name>
<name><surname>Kasahara</surname><given-names>M.</given-names></name>
<name><surname>Imadome</surname><given-names>K.</given-names></name>
</person-group><article-title>Early Detection of Epstein-Barr Virus as a Risk Factor for Chronic High Epstein-Barr Viral Load Carriage at a Living-donor-dominant Pediatric Liver Transplantation Center</article-title><source>Transplantation</source><year>2023</year><volume>107</volume><fpage>1322</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000004429</pub-id><pub-id pub-id-type="pmid">36476718</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00254"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Preiksaitis</surname><given-names>J.</given-names></name>
<name><surname>Allen</surname><given-names>U.</given-names></name>
<name><surname>Bollard</surname><given-names>C.M.</given-names></name>
<name><surname>Dharnidharka</surname><given-names>V.R.</given-names></name>
<name><surname>Dulek</surname><given-names>D.E.</given-names></name>
<name><surname>Green</surname><given-names>M.</given-names></name>
<name><surname>Martinez</surname><given-names>O.M.</given-names></name>
<name><surname>Metes</surname><given-names>D.M.</given-names></name>
<name><surname>Michaels</surname><given-names>M.G.</given-names></name>
<name><surname>Smets</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III&#x02014;Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring</article-title><source>Pediatr. Transplant.</source><year>2024</year><volume>28</volume><fpage>e14471</fpage><pub-id pub-id-type="doi">10.1111/petr.14471</pub-id><pub-id pub-id-type="pmid">37294621</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00254"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomomasa</surname><given-names>D.</given-names></name>
<name><surname>Tanita</surname><given-names>K.</given-names></name>
<name><surname>Hiruma</surname><given-names>Y.</given-names></name>
<name><surname>Hoshino</surname><given-names>A.</given-names></name>
<name><surname>Kudo</surname><given-names>K.</given-names></name>
<name><surname>Azumi</surname><given-names>S.</given-names></name>
<name><surname>Shiota</surname><given-names>M.</given-names></name>
<name><surname>Yamaoka</surname><given-names>M.</given-names></name>
<name><surname>Eguchi</surname><given-names>K.</given-names></name>
<name><surname>Ishimura</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH</article-title><source>Int. J. Hematol.</source><year>2024</year><volume>120</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s12185-024-03786-0</pub-id><pub-id pub-id-type="pmid">38700651</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00254"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawabe</surname><given-names>S.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Gotoh</surname><given-names>K.</given-names></name>
<name><surname>Kojima</surname><given-names>S.</given-names></name>
<name><surname>Matsumoto</surname><given-names>K.</given-names></name>
<name><surname>Kinoshita</surname><given-names>T.</given-names></name>
<name><surname>Iwata</surname><given-names>S.</given-names></name>
<name><surname>Nishiyama</surname><given-names>Y.</given-names></name>
<name><surname>Kimura</surname><given-names>H.</given-names></name>
</person-group><article-title>Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases</article-title><source>Cancer Sci.</source><year>2012</year><volume>103</volume><fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2012.02305.x</pub-id><pub-id pub-id-type="pmid">22497716</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00254"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Shu</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Zeng</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>D.</given-names></name>
<name><surname>Zou</surname><given-names>L.</given-names></name>
</person-group><article-title>Application of Flow Cytometry Combined Fluorescence in Situ Hybridization to Indentify the Lymphocyte Subtypies with Epstein-Barr Virus Infection</article-title><source>Zhongguo Shi Yan Xue Ye Xue Za Zhi</source><year>2022</year><volume>30</volume><fpage>897</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.19746/j.cnki.issn.1009-2137.2022.03.038</pub-id><pub-id pub-id-type="pmid">35680824</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00254"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fournier</surname><given-names>B.</given-names></name>
<name><surname>Boutboul</surname><given-names>D.</given-names></name>
<name><surname>Bruneau</surname><given-names>J.</given-names></name>
<name><surname>Miot</surname><given-names>C.</given-names></name>
<name><surname>Boulanger</surname><given-names>C.</given-names></name>
<name><surname>Malphettes</surname><given-names>M.</given-names></name>
<name><surname>Pellier</surname><given-names>I.</given-names></name>
<name><surname>Dunogu&#x000e9;</surname><given-names>B.</given-names></name>
<name><surname>Terrier</surname><given-names>B.</given-names></name>
<name><surname>Suarez</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection</article-title><source>J. Exp. Med.</source><year>2020</year><volume>217</volume><fpage>e20192262</fpage><pub-id pub-id-type="doi">10.1084/jem.20192262</pub-id><pub-id pub-id-type="pmid">32812031</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00254"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>T.G.</given-names></name>
<name><surname>Rubinstein</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Post-transplant lymphoproliferative disease in children, adolescents, and young adults</article-title><source>Hematol. Oncol.</source><year>2023</year><volume>41</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/hon.3139</pub-id><pub-id pub-id-type="pmid">37294957</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00254"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mynarek</surname><given-names>M.</given-names></name>
<name><surname>Schober</surname><given-names>T.</given-names></name>
<name><surname>Behrends</surname><given-names>U.</given-names></name>
<name><surname>Maecker-Kolhoff</surname><given-names>B.</given-names></name>
</person-group><article-title>Posttransplant lymphoproliferative disease after pediatric solid organ transplantation</article-title><source>Clin. Dev. Immunol.</source><year>2013</year><volume>2013</volume><fpage>814973</fpage><pub-id pub-id-type="doi">10.1155/2013/814973</pub-id><pub-id pub-id-type="pmid">24174972</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00254"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>M.H.</given-names></name>
<name><surname>Montone</surname><given-names>K.T.</given-names></name>
<name><surname>Leahey</surname><given-names>A.M.</given-names></name>
<name><surname>Hodinka</surname><given-names>R.L.</given-names></name>
<name><surname>Salhany</surname><given-names>K.E.</given-names></name>
<name><surname>Kramer</surname><given-names>D.L.</given-names></name>
<name><surname>Deng</surname><given-names>C.</given-names></name>
<name><surname>Tomaszewski</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Post-transplant lymphoproliferative disease in children</article-title><source>Pediatr. Transplant.</source><year>2001</year><volume>5</volume><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3046.2001.005004250.x</pub-id><pub-id pub-id-type="pmid">11472603</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00254"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Esser</surname><given-names>J.W.J.</given-names></name>
<name><surname>Niesters</surname><given-names>H.G.M.</given-names></name>
<name><surname>van der Holt</surname><given-names>B.</given-names></name>
<name><surname>Meijer</surname><given-names>E.</given-names></name>
<name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name>
<name><surname>Gratama</surname><given-names>J.W.</given-names></name>
<name><surname>Verdonck</surname><given-names>L.F.</given-names></name>
<name><surname>L&#x000f6;wenberg</surname><given-names>B.</given-names></name>
<name><surname>Cornelissen</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>4364</fpage><lpage>4369</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.12.4364</pub-id><pub-id pub-id-type="pmid">12036863</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00254"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dike</surname><given-names>P.N.</given-names></name>
<name><surname>Schady</surname><given-names>D.</given-names></name>
<name><surname>Himes</surname><given-names>R.</given-names></name>
<name><surname>Goss</surname><given-names>J.A.</given-names></name>
<name><surname>Guffey</surname><given-names>D.</given-names></name>
<name><surname>Cerminara</surname><given-names>D.</given-names></name>
<name><surname>Mysore</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Incidence and risk factors for chronic rejection in pediatric liver transplantation</article-title><source>Liver Transpl.</source><year>2024</year><pub-id pub-id-type="doi">10.1097/LVT.0000000000000488</pub-id><pub-id pub-id-type="pmid">39311848</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00254"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>J.</given-names></name>
<name><surname>Powell</surname><given-names>J.</given-names></name>
<name><surname>Mather</surname><given-names>M.W.</given-names></name>
<name><surname>Powell</surname><given-names>S.</given-names></name>
<name><surname>Brodlie</surname><given-names>M.</given-names></name>
</person-group><article-title>A review of adenotonsillar hypertrophy and adenotonsillectomy in children after solid organ transplantation</article-title><source>Int. J. Pediatr. Otorhinolaryngol.</source><year>2018</year><volume>114</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2018.08.020</pub-id><pub-id pub-id-type="pmid">30262363</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00254"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pickhardt</surname><given-names>P.J.</given-names></name>
<name><surname>Siegel</surname><given-names>M.J.</given-names></name>
<name><surname>Hayashi</surname><given-names>R.J.</given-names></name>
<name><surname>Kelly</surname><given-names>M.</given-names></name>
</person-group><article-title>Posttransplantation lymphoproliferative disorder in children: Clinical, histopathologic, and imaging features</article-title><source>Radiology</source><year>2000</year><volume>217</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1148/radiology.217.1.r00oc3816</pub-id><pub-id pub-id-type="pmid">11012419</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00254"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akbas</surname><given-names>A.</given-names></name>
<name><surname>Tiede</surname><given-names>C.</given-names></name>
<name><surname>Lemound</surname><given-names>J.</given-names></name>
<name><surname>Maecker-Kolhoff</surname><given-names>B.</given-names></name>
<name><surname>Kreipe</surname><given-names>H.</given-names></name>
<name><surname>Hussein</surname><given-names>K.</given-names></name>
</person-group><article-title>Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation</article-title><source>Transpl. Int.</source><year>2015</year><volume>28</volume><fpage>1299</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1111/tri.12632</pub-id><pub-id pub-id-type="pmid">26147593</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00254"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reiche</surname><given-names>W.</given-names></name>
<name><surname>Tauseef</surname><given-names>A.</given-names></name>
<name><surname>Sabri</surname><given-names>A.</given-names></name>
<name><surname>Mirza</surname><given-names>M.</given-names></name>
<name><surname>Cantu</surname><given-names>D.</given-names></name>
<name><surname>Silberstein</surname><given-names>P.</given-names></name>
<name><surname>Chandan</surname><given-names>S.</given-names></name>
</person-group><article-title>Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review</article-title><source>World J. Transplant.</source><year>2022</year><volume>12</volume><fpage>268</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.5500/wjt.v12.i8.268</pub-id><pub-id pub-id-type="pmid">36159076</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00254"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rubinstein</surname><given-names>J.</given-names></name>
<name><surname>Toner</surname><given-names>K.</given-names></name>
<name><surname>Gross</surname><given-names>T.</given-names></name>
<name><surname>Wistinghausen</surname><given-names>B.</given-names></name>
</person-group><article-title>Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults</article-title><source>Best. Pract. Res. Clin. Haematol.</source><year>2023</year><volume>36</volume><fpage>101446</fpage><pub-id pub-id-type="doi">10.1016/j.beha.2023.101446</pub-id><pub-id pub-id-type="pmid">36907642</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00254"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoyt</surname><given-names>D.</given-names></name>
<name><surname>Hughes</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Ayyad</surname><given-names>H.</given-names></name>
</person-group><article-title>Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings</article-title><source>Radiol. Case Rep.</source><year>2024</year><volume>19</volume><fpage>2168</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1016/j.radcr.2024.02.030</pub-id><pub-id pub-id-type="pmid">38515768</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00254"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taj</surname><given-names>M.M.</given-names></name>
<name><surname>Maecker-Kolhoff</surname><given-names>B.</given-names></name>
<name><surname>Ling</surname><given-names>R.</given-names></name>
<name><surname>Bomken</surname><given-names>S.</given-names></name>
<name><surname>Burkhardt</surname><given-names>B.</given-names></name>
<name><surname>Chiang</surname><given-names>A.K.S.</given-names></name>
<name><surname>Csoka</surname><given-names>M.</given-names></name>
<name><surname>F&#x000fc;reder</surname><given-names>A.</given-names></name>
<name><surname>Haouy</surname><given-names>S.</given-names></name>
<name><surname>Lazic</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Primary post-transplant lymphoproliferative disorder of the central nervous system: Characteristics, management and outcome in 25 paediatric patients</article-title><source>Br. J. Haematol.</source><year>2021</year><volume>193</volume><fpage>1178</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1111/bjh.17398</pub-id><pub-id pub-id-type="pmid">33764500</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00254"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>J.I.</given-names></name>
</person-group><article-title>Epstein-Barr virus infection</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>343</volume><fpage>481</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1056/NEJM200008173430707</pub-id><pub-id pub-id-type="pmid">10944566</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00254"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montanari</surname><given-names>F.</given-names></name>
<name><surname>Orjuela-Grimm</surname><given-names>M.</given-names></name>
</person-group><article-title>Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra</article-title><source>Curr. Hematol. Malig. Rep.</source><year>2021</year><volume>16</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s11899-021-00606-8</pub-id><pub-id pub-id-type="pmid">33544319</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00254"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schober</surname><given-names>T.</given-names></name>
<name><surname>Framke</surname><given-names>T.</given-names></name>
<name><surname>Kreipe</surname><given-names>H.</given-names></name>
<name><surname>Schulz</surname><given-names>T.F.</given-names></name>
<name><surname>Gro&#x000df;hennig</surname><given-names>A.</given-names></name>
<name><surname>Hussein</surname><given-names>K.</given-names></name>
<name><surname>Baumann</surname><given-names>U.</given-names></name>
<name><surname>Pape</surname><given-names>L.</given-names></name>
<name><surname>Schubert</surname><given-names>S.</given-names></name>
<name><surname>Wingen</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Characteristics of early and late PTLD development in pediatric solid organ transplant recipients</article-title><source>Transplantation</source><year>2013</year><volume>95</volume><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e318277e344</pub-id><pub-id pub-id-type="pmid">23222898</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00254"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Swerdlow</surname><given-names>S.H.</given-names></name>
<name><surname>Campo</surname><given-names>E.</given-names></name>
<name><surname>Harris</surname><given-names>N.L.</given-names></name>
<name><surname>Jaffe</surname><given-names>E.S.</given-names></name>
<name><surname>Pileri</surname><given-names>S.A.</given-names></name>
<name><surname>Stein</surname><given-names>H.</given-names></name>
<name><surname>Thiele</surname><given-names>J.</given-names></name>
<name><surname>Vardiman</surname><given-names>J.W.</given-names></name>
</person-group><source>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</source><publisher-name>IARC Press</publisher-name><publisher-loc>Lyon, France</publisher-loc><year>2008</year></element-citation></ref><ref id="B42-viruses-17-00254"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alaggio</surname><given-names>R.</given-names></name>
<name><surname>Amador</surname><given-names>C.</given-names></name>
<name><surname>Anagnostopoulos</surname><given-names>I.</given-names></name>
<name><surname>Attygalle</surname><given-names>A.D.</given-names></name>
<name><surname>Araujo</surname><given-names>I.B.d.O.</given-names></name>
<name><surname>Berti</surname><given-names>E.</given-names></name>
<name><surname>Bhagat</surname><given-names>G.</given-names></name>
<name><surname>Borges</surname><given-names>A.M.</given-names></name>
<name><surname>Boyer</surname><given-names>D.</given-names></name>
<name><surname>Calaminici</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms</article-title><source>Leukemia</source><year>2022</year><volume>36</volume><fpage>1720</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1038/s41375-022-01620-2</pub-id><pub-id pub-id-type="pmid">35732829</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00254"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lauro</surname><given-names>A.</given-names></name>
<name><surname>Arpinati</surname><given-names>M.</given-names></name>
<name><surname>Pinna</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Managing the challenge of PTLD in liver and bowel transplant recipients</article-title><source>Br. J. Haematol.</source><year>2015</year><volume>169</volume><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1111/bjh.13213</pub-id><pub-id pub-id-type="pmid">25377273</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00254"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campo</surname><given-names>E.</given-names></name>
<name><surname>Jaffe</surname><given-names>E.S.</given-names></name>
<name><surname>Cook</surname><given-names>J.R.</given-names></name>
<name><surname>Quintanilla-Martinez</surname><given-names>L.</given-names></name>
<name><surname>Swerdlow</surname><given-names>S.H.</given-names></name>
<name><surname>Anderson</surname><given-names>K.C.</given-names></name>
<name><surname>Brousset</surname><given-names>P.</given-names></name>
<name><surname>Cerroni</surname><given-names>L.</given-names></name>
<name><surname>de Leval</surname><given-names>L.</given-names></name>
<name><surname>Dirnhofer</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee</article-title><source>Blood</source><year>2022</year><volume>140</volume><fpage>1229</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1182/blood.2022015851</pub-id><pub-id pub-id-type="pmid">35653592</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00254"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeStefano</surname><given-names>C.B.</given-names></name>
<name><surname>Desai</surname><given-names>S.H.</given-names></name>
<name><surname>Shenoy</surname><given-names>A.G.</given-names></name>
<name><surname>Catlett</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Management of post-transplant lymphoproliferative disorders</article-title><source>Br. J. Haematol.</source><year>2018</year><volume>182</volume><fpage>330</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/bjh.15263</pub-id><pub-id pub-id-type="pmid">29741774</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00254"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheson</surname><given-names>B.D.</given-names></name>
<name><surname>Fisher</surname><given-names>R.I.</given-names></name>
<name><surname>Barrington</surname><given-names>S.F.</given-names></name>
<name><surname>Cavalli</surname><given-names>F.</given-names></name>
<name><surname>Schwartz</surname><given-names>L.H.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
<name><surname>Lister</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>3059</fpage><lpage>3067</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.54.8800</pub-id><pub-id pub-id-type="pmid">25113753</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00254"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x02019;Huillier</surname><given-names>A.G.</given-names></name>
<name><surname>Dipchand</surname><given-names>A.I.</given-names></name>
<name><surname>Ng</surname><given-names>V.L.</given-names></name>
<name><surname>Hebert</surname><given-names>D.</given-names></name>
<name><surname>Avitzur</surname><given-names>Y.</given-names></name>
<name><surname>Solomon</surname><given-names>M.</given-names></name>
<name><surname>Ngan</surname><given-names>B.</given-names></name>
<name><surname>Stephens</surname><given-names>D.</given-names></name>
<name><surname>Punnett</surname><given-names>A.S.</given-names></name>
<name><surname>Barton</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Posttransplant lymphoproliferative disorder in pediatric patients: Survival rates according to primary sites of occurrence and a proposed clinical categorization</article-title><source>Am. J. Transplant.</source><year>2019</year><volume>19</volume><fpage>2764</fpage><lpage>2774</lpage><pub-id pub-id-type="doi">10.1111/ajt.15358</pub-id><pub-id pub-id-type="pmid">30884098</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00254"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>U.D.</given-names></name>
<name><surname>Preiksaitis</surname><given-names>J.K.</given-names></name>
<collab>AST Infectious Diseases Community of Practice</collab>
</person-group><article-title>Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13652</fpage><pub-id pub-id-type="doi">10.1111/ctr.13652</pub-id><pub-id pub-id-type="pmid">31230381</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00254"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tajima</surname><given-names>T.</given-names></name>
<name><surname>Martinez</surname><given-names>O.M.</given-names></name>
<name><surname>Bernstein</surname><given-names>D.</given-names></name>
<name><surname>Boyd</surname><given-names>S.D.</given-names></name>
<name><surname>Gratzinger</surname><given-names>D.</given-names></name>
<name><surname>Lum</surname><given-names>G.</given-names></name>
<name><surname>Sasaki</surname><given-names>K.</given-names></name>
<name><surname>Tan</surname><given-names>B.</given-names></name>
<name><surname>Twist</surname><given-names>C.J.</given-names></name>
<name><surname>Weinberg</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States</article-title><source>Pediatr. Transplant.</source><year>2024</year><volume>28</volume><fpage>e14763</fpage><pub-id pub-id-type="doi">10.1111/petr.14763</pub-id><pub-id pub-id-type="pmid">38682750</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00254"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Mo</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Liang</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Chang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting V&#x003b4;2(+) T cells activities after hematopoietic transplantation for blood malignancies</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>e000208</fpage><pub-id pub-id-type="doi">10.1136/jitc-2019-000208</pub-id><pub-id pub-id-type="pmid">32221014</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00254"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Lv</surname><given-names>A.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Lam</surname><given-names>K.</given-names></name>
<name><surname>Chan</surname><given-names>G.C.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Targeted activation of human V&#x003b3;9V&#x003b4;2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease</article-title><source>Cancer Cell</source><year>2014</year><volume>26</volume><fpage>565</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.07.026</pub-id><pub-id pub-id-type="pmid">25220446</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00254"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatayama</surname><given-names>Y.</given-names></name>
<name><surname>Hashimoto</surname><given-names>Y.</given-names></name>
<name><surname>Motokura</surname><given-names>T.</given-names></name>
</person-group><article-title>Frequent co-reactivation of Epstein-Barr virus in patients with cytomegalovirus viremia under immunosuppressive therapy and/or chemotherapy</article-title><source>J. Int. Med. Res.</source><year>2020</year><volume>48</volume><fpage>300060520972880</fpage><pub-id pub-id-type="doi">10.1177/0300060520972880</pub-id><pub-id pub-id-type="pmid">33249964</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00254"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kerr</surname><given-names>B.M.</given-names></name>
<name><surname>Lear</surname><given-names>A.L.</given-names></name>
<name><surname>Rowe</surname><given-names>M.</given-names></name>
<name><surname>Croom-Carter</surname><given-names>D.</given-names></name>
<name><surname>Young</surname><given-names>L.S.</given-names></name>
<name><surname>Rookes</surname><given-names>S.M.</given-names></name>
<name><surname>Gallimore</surname><given-names>P.H.</given-names></name>
<name><surname>Rickinson</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage</article-title><source>Virology</source><year>1992</year><volume>187</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(92)90307-B</pub-id><pub-id pub-id-type="pmid">1310556</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00254"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shannon-Lowe</surname><given-names>C.</given-names></name>
<name><surname>Rickinson</surname><given-names>A.B.</given-names></name>
<name><surname>Bell</surname><given-names>A.I.</given-names></name>
</person-group><article-title>Epstein-Barr virus-associated lymphomas</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2017</year><volume>372</volume><elocation-id>20160271</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2016.0271</pub-id><pub-id pub-id-type="pmid">28893938</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00254"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>M.</given-names></name>
<name><surname>Macedo</surname><given-names>C.</given-names></name>
<name><surname>Louis</surname><given-names>K.</given-names></name>
<name><surname>Shi</surname><given-names>T.</given-names></name>
<name><surname>Landsittel</surname><given-names>D.</given-names></name>
<name><surname>Nguyen</surname><given-names>C.</given-names></name>
<name><surname>Shinjoh</surname><given-names>M.</given-names></name>
<name><surname>Michaels</surname><given-names>M.G.</given-names></name>
<name><surname>Feingold</surname><given-names>B.</given-names></name>
<name><surname>Mazariegos</surname><given-names>G.V.</given-names></name>
<etal/>
</person-group><article-title>Distinct association between chronic Epstein-Barr virus infection and T cell compartments from pediatric heart, kidney, and liver transplant recipients</article-title><source>Am. J. Transplant.</source><year>2023</year><volume>23</volume><fpage>1145</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1016/j.ajt.2023.05.007</pub-id><pub-id pub-id-type="pmid">37187296</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00254"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dharnidharka</surname><given-names>V.R.</given-names></name>
<name><surname>Lamb</surname><given-names>K.E.</given-names></name>
<name><surname>Gregg</surname><given-names>J.A.</given-names></name>
<name><surname>Meier-Kriesche</surname><given-names>H.</given-names></name>
</person-group><article-title>Associations between EBV serostatus and organ transplant type in PTLD risk: An analysis of the SRTR National Registry Data in the United States</article-title><source>Am. J. Transplant.</source><year>2012</year><volume>12</volume><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03893.x</pub-id><pub-id pub-id-type="pmid">22226225</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00254"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferla</surname><given-names>V.</given-names></name>
<name><surname>Rossi</surname><given-names>F.G.</given-names></name>
<name><surname>Goldaniga</surname><given-names>M.C.</given-names></name>
<name><surname>Baldini</surname><given-names>L.</given-names></name>
</person-group><article-title>Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>506</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00506</pub-id><pub-id pub-id-type="pmid">32457824</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00254"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morscio</surname><given-names>J.</given-names></name>
<name><surname>Dierickx</surname><given-names>D.</given-names></name>
<name><surname>Tousseyn</surname><given-names>T.</given-names></name>
</person-group><article-title>Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: What do we know so far?</article-title><source>Clin. Dev. Immunol.</source><year>2013</year><volume>2013</volume><fpage>150835</fpage><pub-id pub-id-type="doi">10.1155/2013/150835</pub-id><pub-id pub-id-type="pmid">23690819</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00254"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurwitz</surname><given-names>M.</given-names></name>
<name><surname>Desai</surname><given-names>D.M.</given-names></name>
<name><surname>Cox</surname><given-names>K.L.</given-names></name>
<name><surname>Berquist</surname><given-names>W.E.</given-names></name>
<name><surname>Esquivel</surname><given-names>C.O.</given-names></name>
<name><surname>Millan</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation</article-title><source>Pediatr. Transplant.</source><year>2004</year><volume>8</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3046.2004.00129.x</pub-id><pub-id pub-id-type="pmid">15176965</pub-id>
</element-citation></ref><ref id="B60-viruses-17-00254"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Hamed</surname><given-names>R.</given-names></name>
<name><surname>Bazarbachi</surname><given-names>A.H.</given-names></name>
<name><surname>Mohty</surname><given-names>M.</given-names></name>
</person-group><article-title>Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: A comprehensive review from pathogenesis to forthcoming treatment modalities</article-title><source>Bone Marrow Transplant.</source><year>2020</year><volume>55</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41409-019-0548-7</pub-id><pub-id pub-id-type="pmid">31089285</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00254"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>U.D.</given-names></name>
<name><surname>L&#x02019;Huillier</surname><given-names>A.G.</given-names></name>
<name><surname>Bollard</surname><given-names>C.M.</given-names></name>
<name><surname>Gross</surname><given-names>T.G.</given-names></name>
<name><surname>Hayashi</surname><given-names>R.J.</given-names></name>
<name><surname>H&#x000f6;cker</surname><given-names>B.</given-names></name>
<name><surname>Maecker-Kolhoff</surname><given-names>B.</given-names></name>
<name><surname>Marks</surname><given-names>S.D.</given-names></name>
<name><surname>Mazariegos</surname><given-names>G.V.</given-names></name>
<name><surname>Smets</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: IV-consensus guidelines for the management of post-transplant lymphoproliferative disorders in children and adolescents</article-title><source>Pediatr. Transplant.</source><year>2024</year><volume>28</volume><fpage>e14781</fpage><pub-id pub-id-type="doi">10.1111/petr.14781</pub-id><pub-id pub-id-type="pmid">38808744</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00254"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Mansour</surname><given-names>Z.</given-names></name>
<name><surname>Nelson</surname><given-names>B.P.</given-names></name>
<name><surname>Evens</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies</article-title><source>Curr. Hematol. Malig. Rep.</source><year>2013</year><volume>8</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1007/s11899-013-0162-5</pub-id><pub-id pub-id-type="pmid">23737188</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00254"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choquet</surname><given-names>S.</given-names></name>
<name><surname>Leblond</surname><given-names>V.</given-names></name>
<name><surname>Herbrecht</surname><given-names>R.</given-names></name>
<name><surname>Soci&#x000e9;</surname><given-names>G.</given-names></name>
<name><surname>Stoppa</surname><given-names>A.</given-names></name>
<name><surname>Vandenberghe</surname><given-names>P.</given-names></name>
<name><surname>Fischer</surname><given-names>A.</given-names></name>
<name><surname>Morschhauser</surname><given-names>F.</given-names></name>
<name><surname>Salles</surname><given-names>G.</given-names></name>
<name><surname>Feremans</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3053</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-01-0377</pub-id><pub-id pub-id-type="pmid">16254143</pub-id>
</element-citation></ref><ref id="B64-viruses-17-00254"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oertel</surname><given-names>S.H.K.</given-names></name>
<name><surname>Verschuuren</surname><given-names>E.</given-names></name>
<name><surname>Reinke</surname><given-names>P.</given-names></name>
<name><surname>Zeidler</surname><given-names>K.</given-names></name>
<name><surname>Papp-V&#x000e1;ry</surname><given-names>M.</given-names></name>
<name><surname>Babel</surname><given-names>N.</given-names></name>
<name><surname>Trappe</surname><given-names>R.U.</given-names></name>
<name><surname>Jonas</surname><given-names>S.</given-names></name>
<name><surname>Hummel</surname><given-names>M.</given-names></name>
<name><surname>Anagnostopoulos</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)</article-title><source>Am. J. Transplant.</source><year>2005</year><volume>5</volume><fpage>2901</fpage><lpage>2906</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2005.01098.x</pub-id><pub-id pub-id-type="pmid">16303003</pub-id>
</element-citation></ref><ref id="B65-viruses-17-00254"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evens</surname><given-names>A.M.</given-names></name>
<name><surname>David</surname><given-names>K.A.</given-names></name>
<name><surname>Helenowski</surname><given-names>I.</given-names></name>
<name><surname>Nelson</surname><given-names>B.</given-names></name>
<name><surname>Kaufman</surname><given-names>D.</given-names></name>
<name><surname>Kircher</surname><given-names>S.M.</given-names></name>
<name><surname>Gimelfarb</surname><given-names>A.</given-names></name>
<name><surname>Hattersley</surname><given-names>E.</given-names></name>
<name><surname>Mauro</surname><given-names>L.A.</given-names></name>
<name><surname>Jovanovic</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>1038</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.4961</pub-id><pub-id pub-id-type="pmid">20085936</pub-id>
</element-citation></ref><ref id="B66-viruses-17-00254"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trappe</surname><given-names>R.U.</given-names></name>
<name><surname>Dierickx</surname><given-names>D.</given-names></name>
<name><surname>Zimmermann</surname><given-names>H.</given-names></name>
<name><surname>Morschhauser</surname><given-names>F.</given-names></name>
<name><surname>Mollee</surname><given-names>P.</given-names></name>
<name><surname>Zaucha</surname><given-names>J.M.</given-names></name>
<name><surname>Dreyling</surname><given-names>M.H.</given-names></name>
<name><surname>D&#x000fc;hrsen</surname><given-names>U.</given-names></name>
<name><surname>Reinke</surname><given-names>P.</given-names></name>
<name><surname>Verhoef</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>536</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.69.3564</pub-id><pub-id pub-id-type="pmid">27992268</pub-id>
</element-citation></ref><ref id="B67-viruses-17-00254"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trappe</surname><given-names>R.</given-names></name>
<name><surname>Oertel</surname><given-names>S.</given-names></name>
<name><surname>Leblond</surname><given-names>V.</given-names></name>
<name><surname>Mollee</surname><given-names>P.</given-names></name>
<name><surname>Sender</surname><given-names>M.</given-names></name>
<name><surname>Reinke</surname><given-names>P.</given-names></name>
<name><surname>Neuhaus</surname><given-names>R.</given-names></name>
<name><surname>Lehmkuhl</surname><given-names>H.</given-names></name>
<name><surname>Horst</surname><given-names>H.A.</given-names></name>
<name><surname>Salles</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial</article-title><source>Lancet Oncol.</source><year>2012</year><volume>13</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70300-X</pub-id><pub-id pub-id-type="pmid">22173060</pub-id>
</element-citation></ref><ref id="B68-viruses-17-00254"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>T.G.</given-names></name>
<name><surname>Orjuela</surname><given-names>M.A.</given-names></name>
<name><surname>Perkins</surname><given-names>S.L.</given-names></name>
<name><surname>Park</surname><given-names>J.R.</given-names></name>
<name><surname>Lynch</surname><given-names>J.C.</given-names></name>
<name><surname>Cairo</surname><given-names>M.S.</given-names></name>
<name><surname>Smith</surname><given-names>L.M.</given-names></name>
<name><surname>Hayashi</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): A Children&#x02019;s Oncology Group Report</article-title><source>Am. J. Transplant.</source><year>2012</year><volume>12</volume><fpage>3069</fpage><lpage>3075</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04206.x</pub-id><pub-id pub-id-type="pmid">22883417</pub-id>
</element-citation></ref><ref id="B69-viruses-17-00254"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vase</surname><given-names>M.&#x000d8;.</given-names></name>
<name><surname>Maksten</surname><given-names>E.F.</given-names></name>
<name><surname>Bendix</surname><given-names>K.</given-names></name>
<name><surname>Hamilton-Dutoit</surname><given-names>S.</given-names></name>
<name><surname>Andersen</surname><given-names>C.</given-names></name>
<name><surname>M&#x000f8;ller</surname><given-names>M.B.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>S.S.</given-names></name>
<name><surname>Jespersen</surname><given-names>B.</given-names></name>
<name><surname>Kampmann</surname><given-names>J.</given-names></name>
<name><surname>S&#x000f8;nderg&#x000e5;rd</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders</article-title><source>Leuk. Lymphoma</source><year>2015</year><volume>56</volume><fpage>1677</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.3109/10428194.2014.966242</pub-id><pub-id pub-id-type="pmid">25248878</pub-id>
</element-citation></ref><ref id="B70-viruses-17-00254"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Markouli</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>F.</given-names></name>
<name><surname>Omar</surname><given-names>N.</given-names></name>
<name><surname>Apostolopoulou</surname><given-names>A.</given-names></name>
<name><surname>Dhillon</surname><given-names>P.</given-names></name>
<name><surname>Diamantopoulos</surname><given-names>P.</given-names></name>
<name><surname>Dower</surname><given-names>J.</given-names></name>
<name><surname>Gurnari</surname><given-names>C.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<name><surname>Dima</surname><given-names>D.</given-names></name>
</person-group><article-title>Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5949</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14235949</pub-id><pub-id pub-id-type="pmid">36497432</pub-id>
</element-citation></ref><ref id="B71-viruses-17-00254"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pearse</surname><given-names>W.B.</given-names></name>
<name><surname>Petrich</surname><given-names>A.M.</given-names></name>
<name><surname>Gordon</surname><given-names>L.I.</given-names></name>
<name><surname>Karmali</surname><given-names>R.</given-names></name>
<name><surname>Winter</surname><given-names>J.N.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Kaplan</surname><given-names>J.B.</given-names></name>
<name><surname>Behdad</surname><given-names>A.</given-names></name>
<name><surname>Klein</surname><given-names>A.</given-names></name>
<name><surname>Jovanovic</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV&#x02009;+&#x02009;lymphomas</article-title><source>Leuk. Lymphoma</source><year>2021</year><volume>62</volume><fpage>3493</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1080/10428194.2021.1957867</pub-id><pub-id pub-id-type="pmid">34338127</pub-id>
</element-citation></ref><ref id="B72-viruses-17-00254"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haque</surname><given-names>T.</given-names></name>
<name><surname>Wilkie</surname><given-names>G.M.</given-names></name>
<name><surname>Jones</surname><given-names>M.M.</given-names></name>
<name><surname>Higgins</surname><given-names>C.D.</given-names></name>
<name><surname>Urquhart</surname><given-names>G.</given-names></name>
<name><surname>Wingate</surname><given-names>P.</given-names></name>
<name><surname>Burns</surname><given-names>D.</given-names></name>
<name><surname>McAulay</surname><given-names>K.</given-names></name>
<name><surname>Turner</surname><given-names>M.</given-names></name>
<name><surname>Bellamy</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-12-063008</pub-id><pub-id pub-id-type="pmid">17468341</pub-id>
</element-citation></ref><ref id="B73-viruses-17-00254"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahadeo</surname><given-names>K.M.</given-names></name>
<name><surname>Baiocchi</surname><given-names>R.</given-names></name>
<name><surname>Beitinjaneh</surname><given-names>A.</given-names></name>
<name><surname>Chaganti</surname><given-names>S.</given-names></name>
<name><surname>Choquet</surname><given-names>S.</given-names></name>
<name><surname>Dierickx</surname><given-names>D.</given-names></name>
<name><surname>Dinavahi</surname><given-names>R.</given-names></name>
<name><surname>Duan</surname><given-names>X.</given-names></name>
<name><surname>Gamelin</surname><given-names>L.</given-names></name>
<name><surname>Ghobadi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial</article-title><source>Lancet Oncol.</source><year>2024</year><volume>25</volume><fpage>376</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(23)00649-6</pub-id><pub-id pub-id-type="pmid">38309282</pub-id>
</element-citation></ref><ref id="B74-viruses-17-00254"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>E.</given-names></name>
<name><surname>Paczesny</surname><given-names>S.</given-names></name>
<name><surname>Leblond</surname><given-names>V.</given-names></name>
<name><surname>Seigneurin</surname><given-names>J.M.</given-names></name>
<name><surname>Stern</surname><given-names>M.</given-names></name>
<name><surname>Achkar</surname><given-names>A.</given-names></name>
<name><surname>Bauwens</surname><given-names>M.</given-names></name>
<name><surname>Delwail</surname><given-names>V.</given-names></name>
<name><surname>Debray</surname><given-names>D.</given-names></name>
<name><surname>Duvoux</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>1590</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.6.1590</pub-id><pub-id pub-id-type="pmid">11238096</pub-id>
</element-citation></ref><ref id="B75-viruses-17-00254"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simmons</surname><given-names>H.Z.</given-names></name>
<name><surname>Bazzell</surname><given-names>A.F.</given-names></name>
<name><surname>Dains</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Adverse Effects of Virus-Specific T-Cell Therapy: An Integrative Review</article-title><source>J. Adv. Pract. Oncol.</source><year>2019</year><volume>10</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">31538024</pub-id>
</element-citation></ref><ref id="B76-viruses-17-00254"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Bhagat</surname><given-names>S.S.</given-names></name>
<name><surname>Parker</surname><given-names>R.A.</given-names></name>
<name><surname>&#x000d6;st&#x000f6;r</surname><given-names>A.J.K.</given-names></name>
</person-group><article-title>Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials</article-title><source>Rheumatology</source><year>2011</year><volume>50</volume><fpage>552</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq343</pub-id><pub-id pub-id-type="pmid">21078627</pub-id>
</element-citation></ref><ref id="B77-viruses-17-00254"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>S.F.</given-names></name>
<name><surname>Green</surname><given-names>M.</given-names></name>
</person-group><article-title>Chronic Epstein-Barr viral load carriage after pediatric organ transplantation</article-title><source>Front. Pediatr.</source><year>2024</year><volume>12</volume><elocation-id>1335496</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2024.1335496</pub-id><pub-id pub-id-type="pmid">38357509</pub-id>
</element-citation></ref><ref id="B78-viruses-17-00254"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Ho</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Ni</surname><given-names>Y.</given-names></name>
<name><surname>Hsu</surname><given-names>H.</given-names></name>
<name><surname>Jeng</surname><given-names>Y.</given-names></name>
<name><surname>Chang</surname><given-names>M.</given-names></name>
</person-group><article-title>Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation</article-title><source>J. Formos. Med. Assoc.</source><year>2019</year><volume>118</volume><fpage>1362</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2018.12.007</pub-id><pub-id pub-id-type="pmid">30612881</pub-id>
</element-citation></ref><ref id="B79-viruses-17-00254"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seo</surname><given-names>E.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>K.M.</given-names></name>
<name><surname>Kim</surname><given-names>D.Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
</person-group><article-title>Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients</article-title><source>Pediatr. Transplant.</source><year>2020</year><volume>24</volume><fpage>e13666</fpage><pub-id pub-id-type="doi">10.1111/petr.13666</pub-id><pub-id pub-id-type="pmid">32067332</pub-id>
</element-citation></ref><ref id="B80-viruses-17-00254"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>M.</given-names></name>
<name><surname>Squires</surname><given-names>J.E.</given-names></name>
<name><surname>Chinnock</surname><given-names>R.E.</given-names></name>
<name><surname>Comoli</surname><given-names>P.</given-names></name>
<name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name>
<name><surname>Dulek</surname><given-names>D.E.</given-names></name>
<name><surname>Esquivel</surname><given-names>C.O.</given-names></name>
<name><surname>H&#x000f6;cker</surname><given-names>B.</given-names></name>
<name><surname>L&#x02019;Huillier</surname><given-names>A.G.</given-names></name>
<name><surname>Mazariegos</surname><given-names>G.V.</given-names></name>
<etal/>
</person-group><article-title>The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: II&#x02014;Consensus guidelines for prevention</article-title><source>Pediatr. Transplant.</source><year>2024</year><volume>28</volume><fpage>e14350</fpage><pub-id pub-id-type="doi">10.1111/petr.14350</pub-id><pub-id pub-id-type="pmid">36369745</pub-id>
</element-citation></ref><ref id="B81-viruses-17-00254"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baker</surname><given-names>A.</given-names></name>
<name><surname>Frauca Remacha</surname><given-names>E.</given-names></name>
<name><surname>Torres Canizales</surname><given-names>J.</given-names></name>
<name><surname>Bravo-Gallego</surname><given-names>L.Y.</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>E.</given-names></name>
<name><surname>Alonso Melgar</surname><given-names>A.</given-names></name>
<name><surname>Mu&#x000f1;oz Bartolo</surname><given-names>G.</given-names></name>
<name><surname>Garcia Guereta</surname><given-names>L.</given-names></name>
<name><surname>Ramos Boluda</surname><given-names>E.</given-names></name>
<name><surname>Mozo</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Current Practices on Diagnosis, Prevention and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Patients after Solid Organ Transplantation: Results of ERN TransplantChild Healthcare Working Group Survey</article-title><source>Children</source><year>2021</year><volume>8</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.3390/children8080661</pub-id><pub-id pub-id-type="pmid">34438552</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00254-f001"><label>Figure 1</label><caption><p>Algorithm for EBV surveillance, diagnosis and management.</p></caption><graphic xlink:href="viruses-17-00254-g001" position="float"/></fig><fig position="float" id="viruses-17-00254-f002"><label>Figure 2</label><caption><p>Treatment strategies for EBV PTLD vary and may include a reduction in immunosuppression, the use of chemotherapy agents, anti-CD20 monoclonal antibodies, and cytotoxic T lymphocytes. EBV: Epstein&#x02013;Barr virus; PTLD: post-transplant lymphoproliferative disorder. (This schematic was created using Servier Medical Art templates, provided by Servier, licensed under a Creative Commons Attribution 4.0 international license; <uri xlink:href="https://smart.servier.com">https://smart.servier.com</uri>).</p></caption><graphic xlink:href="viruses-17-00254-g002" position="float"/></fig><table-wrap position="float" id="viruses-17-00254-t001"><object-id pub-id-type="pii">viruses-17-00254-t001_Table 1</object-id><label>Table 1</label><caption><p>EBV detection methods.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Test</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Detection Method </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biomarker</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody Serology</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detects antibodies to viral components of EBV and helps indicate temporality of infection.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole blood</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Acute infection:</italic> Anti-VCA IgM, Anti-EA<break/><italic toggle="yes">Post-acute infection:</italic> Anti-EBNA<break/><italic toggle="yes">Acute infection and lifetime persistence:</italic> Anti-VCA IgG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAAT (PCR)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detects and quantifies EBV DNAemia through nucleic acid amplification of peripheral blood.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole blood or plasma</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV DNA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBER Flow FISH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uses fluorescence in situ hybridization to detect EBV-encoded small RNAs (EBERs). Can determine lytic vs. latent stages and differentiate EBV infections across various cell types.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tissue or blood</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV-encoded small RNAs (EBERs)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00254-t002"><object-id pub-id-type="pii">viruses-17-00254-t002_Table 2</object-id><label>Table 2</label><caption><p>WHO 2017 classification of PTLD vs. 2022 International Consensus Classification (ICC) of PTLD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2017 WHO Classification</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2022 International Consensus Classification (ICC) *</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-destructive PTLD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Hyperplasias arising during immune deficiency/dysregulation
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Polymorphic PTLD
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Polymorphic lymphoproliferative disorders arising during immune deficiency/dysregulation
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Monomorphic PTLD, classic Hodgkin lymphoma PTLD
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Lymphomas arising during immune deficiency/dysregulation
</td></tr></tbody></table><table-wrap-foot><fn><p>* Under the overarching category &#x0201c;Lymphoid proliferations and lymphomas associated with immune deficiency and dysregulation&#x0201d;, which encompasses other diseases outside of PTLD that are not included here.</p></fn></table-wrap-foot></table-wrap></floats-group></article>